ESW vision

What ESW vision does

ESW Vision (legal entity E-SWIN, SAS, headquartered in Houdan, France) is a privately held medical device company that develops, manufactures, and commercializes hardware and consumables for the diagnosis and treatment of dry eye disease, with a specific focus on Meibomian Gland Dysfunction (MGD). Its core technology is IRPL® (Intense Regulated Pulsed Light), a controlled-pulse light modality used in two treatment devices: E-Eye, positioned as the first certified IRPL® device for MGD and targeted at clinical settings, and tearstim®, a compact 6.4kg device designed for optometrists, opticians, and multi-location operators. On the diagnostic side, the company offers tearcheck® and tearcheck® LITE screening devices, which incorporate patented tests including TFSE® (Tear Film Stability Evaluation) and OSIE® (Ocular Surface Inflammatory Risk Evaluation) alongside NIBUT, meibography IR, eye redness, Demodex detection, abortive blinking analysis, and tear meniscus measurement, delivering eight exams in under ten minutes. A clinical evidence base of 2,400+ patients across 14 years and reference in the TFOS-DEWS-III digest underpin the technology's credibility.

The company operates a hardware-plus-consumables revenue model: devices are sold via direct, quote-based enterprise field sales to ophthalmologists, optometrists, optical groups, and hospital chains, with recurring revenue from consumables (optical gel sachets, lamp kits) and accessories managed through the connect® platform. Go-to-market is multi-channel, combining direct sales in France, Austria, and the US with distributor partnerships internationally, including DEMServices (India, from February 2023) and Appasamy Associates (India, from April 2025). The company also runs a patient-facing platform, Keep Your Eyes Fit, and an audio thought-leadership channel, The Ocular Insider podcast. End customers are predominantly eye care professionals; pricing is not publicly disclosed, and the company had 11-50 employees as of the most recent firmographic snapshot.

Name

ESW vision

Legal name

E-SWIN

Website

https://esw-vision.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

ESW Vision is a France-based medical device company that develops IRPL® light-based treatment devices (E-Eye, tearstim®) and tearcheck® screening systems for diagnosing and managing dry eye disease and Meibomian Gland Dysfunction, sold to ophthalmologists, optometrists, and hospital chains.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation) (HLAHAJAF)

Keywords

• Dry eye treatment
• Ocular diagnostics
• Meibomian gland dysfunction
• Medical devices
• Intense pulse light therapy

Headquarters

HQ city

Houdan

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales: Sale of diagnostic and treatment medical devices including tearcheck® screening systems, E-Eye treatment devices, and tearstim® compact treatment devices to eye care professionals, hospitals, and optical chains.
2. Consumables: Recurring revenue from consumable products including optical gel sachets for IRPL® treatment, lamp kits, and other treatment accessories. Consumables are managed through the connect® platform.
3. Accessories: Sale of accessories including carry bags, suitcases, custom-made dust covers, and other workflow enhancement products.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

ESW Vision designs, manufactures, and sells medical devices for the screening and treatment of dry eye disease and Meibomian Gland Dysfunction (MGD). Its portfolio includes the tearcheck® and tearcheck® LITE diagnostic screening systems and the E-Eye and tearstim® IRPL® (Intense Regulated Pulse Light) treatment devices, supported by recurring consumables (gel sachets, lamp kits) and the connect® device-management platform for eye care professionals, hospitals, and optical chains.

Product overview

ESW Vision offers a comprehensive dry eye management solution comprising two product categories: screening (tearcheck® and tearcheck® LITE devices) and treatment (E-Eye and tearstim® IRPL® devices). The tearcheck® product line provides dry eye examination with 8 exams including TFSE®/NIBUT, Meibography IR, Eye Redness, Demodex, and OSIE®, while the E-Eye/tearstim® product line delivers IRPL® treatment for Meibomian Gland Dysfunction. The company also provides accessories (gel sachets, carry cases), the connect® device management platform, and the Keep Your Eyes Fit patient portal.

Differentiator

Problem solved

Functional benefit

Brands

• tearcheck®: Dry eye screening device featuring patented TFSE® and OSIE® tests for comprehensive dry eye examination
• tearcheck® LITE
• E-Eye
• tearstim®
• connect®
• Keep Your Eyes Fit

Products and services

• tearcheck® Comprehensive dry eye screening device featuring two patented tests (TFSE® and OSIE®) and up to eight examination capabilities including tear film stability, NIBUT, Meibography IR, eye redness, Demodex detection, abortive blinking, and tear meniscus measurement, delivering results in under 10 minutes. Designed for ophthalmologists, optometrists, and eye care clinics.
• tearcheck® LITE Lightweight, mobile variant of the tearcheck® screening device optimized for portability between clinic locations and for use in smaller practice spaces. Targeted at eye care professionals requiring flexible dry eye screening.
• E-Eye First certified IRPL® (Intense Regulated Pulse Light) device for the treatment of Meibomian Gland Dysfunction (MGD). Delivers controlled light pulses to stimulate meibomian glands, providing instant and cumulative relief with no downtime and a recommended protocol of sessions on Day 1, Day 15, and Day 45. Sold to eye care professionals and clinics.
• tearstim® Compact IRPL® treatment device weighing 6.4 kg (versus 11 kg for E-Eye), designed for optometrists and opticians and suitable for multi-location operation within hospital chains and optical groups. Delivers the same IRPL® MGD therapy in a space-saving form factor.
• Accessories and consumables Recurring-use consumables and accessories for IRPL® treatment devices, including optical gel sachets with smart dispenser, L/XL consumables with extended flash capacity, carry bags and suitcases for device transport, and custom dust covers. Sold to existing device customers.
• connect® Platform Online platform that allows customers to manage all ESW Vision devices and consumables from a single place, providing exclusive features and services such as device tracking and consumables reordering. Requires account creation; targeted at existing device customers.
• Keep Your Eyes Fit Patient-facing website that enables eye fitness testing and basic dry eye awareness, supporting patient engagement and continuity of eye health between clinic visits.

Quantifiable outcome

• IRPL® treatment sessions recommended at Day 1, Day 15, and Day 45 with optional session at Day 75
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Appasamy AssociatescoreChannel Partner/ Reseller/ Distributor · 1 April 2025Strategic partnership announced in April 2025 for distribution of ESW Vision's dry eye management solutions in India. Appasamy Associates is a key player in the Indian ophthalmology market.
• DEMServices (India)coreChannel Partner/ Reseller/ Distributor · 1 February 2023ESW Vision started operations in India through partnership with DEMServices in February 2023, establishing market presence for dry eye solutions in the region.
• Market Entry - UScoreOthers · 1 November 2021ESW Vision entered the US market in November 2021, establishing direct market presence for dry eye management solutions in the United States.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Alcon: Alcon markets the iLUX MGD treatment device, directly competing with ESW Vision's IRPL®-based portfolio for ophthalmologist and optometry practices treating dry eye/MGD patients.
• SightSciences: SightSciences sells TearCare, a thermal MGD treatment system, and the SightPRO diagnostic platform, directly competing with ESW Vision across both the diagnostic and therapeutic sides of the dry eye workflow.
• Lumenis (Boston Scientific): Lumenis (acquired by Boston Scientific) sells the M22 IPL system, a direct competitor to ESW Vision's IRPL® E-Eye for treating MGD/dry eye disease. Both target ophthalmologists and optometrists with light-based MGD therapy devices.
• Johnson & Johnson Vision (TearScience/LipiFlow): J&J Vision's LipiFlow Thermal Pulsation System is a leading MGD treatment device, directly competing with ESW Vision's E-Eye and tearstim® IRPL® devices. Both address the same MGD/dry eye clinical pathway.

Peers

• Oculus (Optikgeräte):

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCbBG-kFlMHl8dSYaNHDtWhw
• Facebookfacebook.com/eswvision
• LinkedInlinkedin.com/company/esw-vision
• Instagraminstagram.com/eswvision

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ESW vision